


(-)-Eseroline fumarate

Cat. No.:	HY-129101
CAS No.:	70310-73-5
Molecular Formula:	C ₁₇ H ₂₂ N ₂ O ₅
Molecular Weight:	334.37
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(-)-Eseroline fumarate is a metabolic of Physostigmine (HY-N6608), an AChE inhibitor. (-)-Eseroline fumarate elicits a leakage of lactic acid dehydrogenase (LDH) from cancer cells. (-)-Eseroline fumarate also induces the release of adenine nucleotides and 5-hydroxytryptamine (5-HT) from neuronal cells, thus induce cell death. (-)-Eseroline fumarate inhibits the electrically evoked twitches of the mouse vas deferens and of the guinea-pig ileum ^{[1][2]} .
In Vitro	(-)-Eseroline fumarate (0.5 mM; 0-25 hr) time-dependently induces LDH leakage of neuronal cell culture systems: mouse neuroblastoma N1E-115, rat glioma C6, and neuroblastoma-glioma hybrid NG 108-15 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	(-)-Eseroline fumarate (HCl; 10 mg/kg; i.v.; single dose) induces the release of 5-HT from cerebral cortex in adult mongrel cats ^[2] . (-)-Eseroline fumarate (salicylate; 9 mg/kg; s.c.; single dose) shows analgesic effect and strongly reduces antinociceptive effect of Physostigmine (HY-N6608) in the mouse tail-flick test ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Somani SM, et al. Eseroline, a metabolite of physostigmine, induces neuronal cell death. *Toxicol Appl Pharmacol.* 1990 Oct;106(1):28-37.
- [2]. Bartolini A, et al. Eseroline: a new antinociceptive agent derived from physostigmine with opiate receptor agonist properties. *Experimental in vivo and in vitro studies on cats and rodents.* *Neurosci Lett.* 1981 Sep 1;25(2):179-83.
- [3]. Harris LS, et al. Narcotic-antagonist analgesics: interactions with cholinergic systems. *J Pharmacol Exp Ther.* 1969 Sep;169(1):17-22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA